SLIM: A Gateway to the Adoption of High-Resolution Ion Mobility for Biotherapeutic Peptide Mapping

MOBILion Eye
MOBILion Favicon
MOBILion Systems, Inc.
August 4, 2021

x min read

The demand for protein therapeutics, such as recombinant human proteins, monoclonal antibodies (mAbs), and fusion proteins, has grown significantly over the past decade. Often developed to treat previously unmet clinical needs, these biotherapeutics require increasingly advanced analytical technology for detection, identification, quantitation, and quality control (QC)/monitoring of molecular attributes. Melissa Sherman at MOBILion Systems Inc and Jared Auclair, Associate Dean, look over the adoption of high-resolution ion mobility for biotherapeutic peptide mapping.


Schedule a Chat Today!

MOBILion Wave Hero